Allogene Therapeutics
- Company typePublic
- Founded2017
- HeadquartersSouth San Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Allogene Therapeutics firmographics
Firmographics- Name
- Allogene Therapeutics
- Legal name
- Allogene Therapeutics, Inc.
- Website
- https://allogene.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Allogene Therapeutics industry classification
Industry- Product category
- Allogeneic CAR T Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where Allogene Therapeutics is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Allogene Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Product Revenue: Allogene is a clinical-stage company with no commercialized products. The company is developing allogeneic CAR T cell therapies for blood cancers, solid tumors, and autoimmune diseases. Revenue will be generated from product sales upon regulatory approval.
- Licensing and Royalties: Cellectis is eligible to receive up to $340 million in development and sales milestone payments plus low double-digit royalties on net sales of cema-cel under the Servier Agreement.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Allogene Therapeutics product offering
Product offeringCore offering
Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies using T cells from healthy donors that are engineered with chimeric antigen receptors (CARs) and modified via gene editing to evade the patient's immune system. Its clinical pipeline includes cema-cel (anti-CD19) for first-line consolidation in MRD-positive large B-cell lymphoma, ALLO-316 (anti-CD70) for renal cell carcinoma, and ALLO-329 (dual CD19/CD70) for autoimmune diseases such as lupus, myositis, and scleroderma. All products are investigational and currently distributed only through clinical trials.
Product overview
Allogene Therapeutics is a clinical-stage biotechnology company developing the AlloCAR T platform—an investigational allogeneic CAR T cell therapy system derived from healthy donor T cells. The platform enables off-the-shelf treatment with potential to serve 100+ patients from a single manufacturing run. The core product portfolio includes: cema-cel (cemacabtagene ansegedleucel) for first-line consolidation treatment of MRD-positive large B-cell lymphoma in the pivotal ALPHA3 trial; ALLO-316 for CD70-positive solid tumors including renal cell carcinoma in the TRAVERSE trial; and ALLO-329, a next-generation dual-targeted CD19/CD70 CAR T for autoimmune diseases in the RESOLUTION trial. The platform is enhanced by proprietary technologies including Dagger® for immune evasion. Manufacturing is conducted in-house at Cell Forge 1 in Newark, California.
Differentiator
Problem solved
Functional benefit
Brands
- AlloCAR T: The company's proprietary allogeneic CAR T cell product platform
- Dagger
- Cell Forge 1
- TurboCAR
Products and services
- Cemacabtagene ansegedleucel (cema-cel)
Quantifiable outcome
- 58.3% MRD clearance rate with cema-cel vs 16.7% in observation arm in ALPHA3 interim futility analysis
- +3 more outcomes
Companies that use Allogene Therapeutics
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Allogene Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
Allogene Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and secondary.
- ServiercoreServier holds exclusive license to anti-CD19 AlloCAR T investigational products from Cellectis and has granted Allogene exclusive rights to cema-cel and ALLO-501 in the U.S., all EU Member States and the United Kingdom. Servier retains rights in other territories. Favorable arbitration ruling in December 2025 reaffirmed Allogene's full development and commercial control in U.S., EU, and UK.
- CellectiscoreAllogene assumed Pfizer's strategic collaboration and licensing agreement with Cellectis, with exclusive rights to develop and commercialize allogeneic CAR T therapy programs directed at select targets. Cellectis's UCART19 technology underlies cema-cel (ALLO-501A). Cellectis is eligible to receive up to $340 million in development and sales milestone payments plus low double-digit royalties on net sales of cema-cel under the Servier Agreement.
- Foresight DiagnosticscoreAllogene partnered with Foresight Diagnostics to use their investigational Foresight CLARITY™ MRD assay (powered by PhasED-Seq™) to determine enrollment eligibility for the ALPHA3 trial after first-line treatment for LBCL. The ALPHA3 trial is the first prospective trial to incorporate this investigational MRD testing for patient selection.
- Arbor BiotechnologiessecondaryCollaboration and global gene editing licensing agreement with Arbor Biotechnologies leveraging their CRISPR gene-editing technology to support advancement of next generation allogeneic CAR T platform in autoimmune disease.
- AntionsecondaryCollaboration and global license agreement for Antion's miRNA technology allowing tunable and simultaneous silencing of multiple targets from a single gene construct. Allogene plans to deploy Antion's multiplex miRNA with other technologies to enable next-generation strategies for immune evasion.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Allogene Therapeutics competitors and assessment
Company assessmentDirect peers
- Cellectis: French clinical-stage biotech and the underlying technology licensor for Allogene's cema-cel/ALLO-501 (UCART19 platform). Develops its own allogeneic CAR T candidates using TALEN gene editing, making it a direct peer and counterparty.
- Fate Therapeutics: Clinical-stage biotech developing iPSC-derived off-the-shelf NK and T-cell therapies for cancer and autoimmune disease. Closely comparable platform strategy to Allogene's off-the-shelf cell therapy approach.
- Precision Biosciences: Clinical-stage cell therapy company developing allogeneic CAR T candidates (e.g., PBCAR19B) using ARCUS gene-editing. Direct competitor targeting similar hematology indications.
- Caribou Biosciences: Clinical-stage allogeneic CAR T developer (CB-010, CB-011) using CRISPR-based gene editing for hematologic malignancies. Direct competitor to Allogene in the off-the-shelf CAR T space.
- Atara Biotherapeutics: Allogeneic T-cell therapy developer (tab-cel/EBVALLO) using a similar off-the-shelf model for oncology indications. Direct peer in the allogeneic cell therapy category.
- CRISPR Therapeutics: Clinical-stage gene-editing biotech developing allogeneic CAR T therapies (e.g., CTX112) for hematologic malignancies and autoimmune disease. Direct competitor in off-the-shelf CAR T with overlapping gene-editing approach.
Emerging players
- Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T therapies (Tecelra, lete-cel) for solid tumors. Comparable cell therapy modality and engineering approach, focused on solid tumor indications.
Broad incumbents
- Bristol Myers Squibb: Major oncology incumbent with approved autologous CAR T therapies (Breyanzi, Abecma) and bispecific antibodies in LBCL. Competes in the same patient populations Allogene is targeting with cema-cel.
- Gilead Sciences (Kite Pharma): Owner of Yescarta (autologous CAR T) and Allogene founders' prior employer. Dominant incumbent in the CAR T market; Allogene's allogeneic platform is positioned as the off-the-shelf alternative to Gilead's autologous franchise.
- Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi for solid tumors. Adjacent cell therapy modality competing for similar oncology infrastructure and patient populations.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Allogene Therapeutics social profiles
Digital presenceAllogene Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allogene Therapeutics leadership team
Management profileNumber of profiles
Profiles9 records
Allogene Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allogene Therapeutics M&A and investment
M&A and investmentM&A
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allogene Therapeutics
What does Allogene Therapeutics do?
Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies using T cells from healthy donors that are engineered with chimeric antigen receptors (CARs) and modified via gene editing to evade the patient's immune system. Its clinical pipeline includes cema-cel (anti-CD19) for first-line consolidation in MRD-positive large B-cell lymphoma, ALLO-316 (anti-CD70) for renal cell carcinoma, and ALLO-329 (dual CD19/CD70) for autoimmune diseases such as lupus, myositis, and scleroderma. All products are investigational and currently distributed only through clinical trials.
Is Allogene Therapeutics a public or private company?
Allogene Therapeutics is a public company. It is classified as public and is currently operating.
When was Allogene Therapeutics founded?
Allogene Therapeutics was founded in 2017. It employs 101 to 250 people.
Where is Allogene Therapeutics based?
Allogene Therapeutics is headquartered in South San Francisco, United States, in the North America region.
How does Allogene Therapeutics make money?
Two revenue lines are on record. Product Revenue is the primary driver. The others are licensing and Royalties.
Who are Allogene Therapeutics's main competitors?
Direct peers on record are Cellectis, Fate Therapeutics, Precision Biosciences, Caribou Biosciences, Atara Biotherapeutics and CRISPR Therapeutics. Adaptimmune is listed as an emerging player. Broad incumbents are Bristol Myers Squibb, Gilead Sciences (Kite Pharma) and Iovance Biotherapeutics.
Does Allogene Therapeutics have an API?
No public API is recorded for Allogene Therapeutics.
What industry is Allogene Therapeutics in?
Allogene Therapeutics's product category is Allogeneic CAR T Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.